

Figure 1

(±)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-1yl)-4(1H-indol-3-yl) pyrrolidine-2, 5-dione



(±)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-1-yl)-4(1H-indol-3-yl) pyrrolidine-2, 5-dione.






(±)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1- ij] quinolin-1-yl)-4-(1H-indol-3-yl) pyrrolidine-2, 5-dione
MDA-MB-231
0 0.1 0.25μM
0.5 1 2μM
Paca-2
0 0.1 0.25μM
0.5 1 2μM
(±)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-1yl)-4-(1H-indol-3-yl) pyrrolidine-2, 5-dione
MDA-MB-231
0 0.1 0.25μM
0.5 1 2μM
Paca-2
0 0.1 0.25μM
0.5 1 2μM


FIG. 2

(-)-trans-3-(5,6-dihydro-4*H*-pyrrolo [3,2,1-*ij*] quinolin-1-yl)-4-(1*H*-indol-3-yl) pyrrolidine-2, 5-dione



LC_{50} = 0.62 µM

(+)-trans-3-(5,6-dihydro-4*H*-pyrrolo [3,2,1-*ij*] quinolin-1-yl)-4-(1*H*-indol-3-yl) pyrrolidine-2, 5-dione



LC_{50} = 4.1 µM

FIG. 3



(±)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-1yl)-4(1H-indol-3-yl) pyrrolidine-2, 5-dione
(±)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-1-yl)-4(1H-indol-3-yl) pyrrolidine-2, 5-dione
μM
Control
0.05
0.5
10
0.05
0.5
10

FIG. 4





FIG. 5A



A= (-)-trans-3-(5,6-dihydro-4*H*-pyrrolo [3,2,1-*ij*] quinolin-1-yl)-4-(1*H*-indol-3-yl) pyrrolidine-2, 5-dione

B= (+)-trans-3-(5,6-dihydro-4*H*-pyrrolo [3,2,1-*ij*] quinolin-1-yl)-4-(1*H*-indol-3-yl) pyrrolidine-2, 5-dione

FIG. 5B



Control
(-)-trans Treated

FIG. 6



120
100
80
60
40
20
0
% Invasion
0
0.1
0.25
0.5
0.75
1
(-)- Trans [μM]

FIG. 7



Control
(-)-Trans 200mg/kg po qd
Mean Tumor Volume, mm3
1400
1200
1000
800
600
400
200
0
0
8
11
15
18
22
25
32
37
39
44
47
51
Days Post Innoculation

FIG. 8



Control
(-)-Trans 200mg/kg po qd
(-)-Trans 300mg/kg po qd
Mean Tumor Volume, mm3
1800
1600
1400
1200
1000
800
600
400
200
0
0 8 12 15 19 22 26 29 33 37 40
Days Post Innoculation

FIG. 9A



control
(-)-Trans 200mg/kg po qd
(-)-Trans 300mg/kg po qd
Mean Tumor Volume, mm3
1200
1000
800
600
400
200
0
0 17 20 24 27 33 38 42 46 49 54 59 63
Days Post Innoculation

FIG. 9B



Control
100 mg/kg po qd
200 mg/kg po qd
300 mg/kg po qd
Mean Tumor Volume, mm3
1400
1200
1000
800
600
400
200
0
0
7
10
21
25
29
32
35
38
42
48
Days Post Innoculation

FIG. 9C



Control
200 mg/kg po qd
Mean Tumor Volume, mm3
1400
1200
1000
800
600
400
200
0
0
10
14
18
21
25
28
33
36
40
43
46
Days Post Innoculation

FIG. 9D




FIG. 10

A= (-)-trans-3-(5,6-dihydro-4*H*-pyrrolo [3,2,1-*ij*] quinolin-1-yl)-4-(1*H*-indol-3-yl) pyrrolidine-2, 5-dione





FIG. 11A



A= (-)-trans-3-(5,6-dihydro-4*H*-pyrrolo [3,2,1-*ij*] quinolin-1-yl)-4-(1*H*-indol-3-yl) pyrrolidine-2, 5-dione

FIG. 11B




FIG. 12A




FIG. 12B




FIG. 13A




FIG. 13B




FIG. 14




FIG. 15A




FIG. 15B




FIG. 16




FIG. 17A




FIG. 17B